IL3RA and acute lymphoblastic leukemia: A phase I/II trial is ongoing to assess safety, tolerability, PK, immunogenicity, and preliminary antileukemic activity of IMGN632 as a monotherapy in patients with CD123+ disease (AML, BPDCN, ALL) (NCT03386513).